CH675684A5 - - Google Patents
Download PDFInfo
- Publication number
- CH675684A5 CH675684A5 CH4221/87A CH422187A CH675684A5 CH 675684 A5 CH675684 A5 CH 675684A5 CH 4221/87 A CH4221/87 A CH 4221/87A CH 422187 A CH422187 A CH 422187A CH 675684 A5 CH675684 A5 CH 675684A5
- Authority
- CH
- Switzerland
- Prior art keywords
- elements
- ratios
- concentrations
- compositions
- values
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 239000002366 mineral element Substances 0.000 claims abstract description 13
- 229910052701 rubidium Inorganic materials 0.000 claims description 22
- 229910052725 zinc Inorganic materials 0.000 claims description 21
- 229910052700 potassium Inorganic materials 0.000 claims description 20
- 239000011573 trace mineral Substances 0.000 claims description 12
- 235000013619 trace mineral Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 210000001789 adipocyte Anatomy 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000011701 zinc Substances 0.000 description 38
- 239000011777 magnesium Substances 0.000 description 27
- 239000011669 selenium Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 239000011575 calcium Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000011651 chromium Substances 0.000 description 8
- 239000010949 copper Substances 0.000 description 8
- 229910052749 magnesium Inorganic materials 0.000 description 8
- 239000011572 manganese Substances 0.000 description 8
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 7
- 241000894007 species Species 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- 229910052748 manganese Inorganic materials 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052711 selenium Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229940091258 selenium supplement Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960001471 sodium selenite Drugs 0.000 description 3
- 239000011781 sodium selenite Substances 0.000 description 3
- 235000015921 sodium selenite Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000021321 essential mineral Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000694 mesotherapy Methods 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- HUSXNIFVQFHSEA-UHFFFAOYSA-N 2-hydroxypropanoic acid;hydrochloride Chemical compound Cl.CC(O)C(O)=O HUSXNIFVQFHSEA-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000009546 growth abnormality Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Silicon Polymers (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8711579A FR2619313B1 (fr) | 1987-08-14 | 1987-08-14 | Nouvelles compositions d'elements mineraux et/ou oligoelements et leur procede de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH675684A5 true CH675684A5 (forum.php) | 1990-10-31 |
Family
ID=9354201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH4221/87A CH675684A5 (forum.php) | 1987-08-14 | 1987-10-28 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0306377B1 (forum.php) |
| AT (1) | ATE72984T1 (forum.php) |
| AU (1) | AU625310B2 (forum.php) |
| CH (1) | CH675684A5 (forum.php) |
| DE (1) | DE3868791D1 (forum.php) |
| ES (1) | ES2034321T3 (forum.php) |
| FR (1) | FR2619313B1 (forum.php) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995013080A1 (en) * | 1993-11-08 | 1995-05-18 | Ashmont Holdings Limited | Application of trace elements to animals |
| HUT72422A (en) * | 1994-04-20 | 1996-04-29 | Beres Export Import Rt | Aquous concentrate and process for its preparation |
| AUPN104895A0 (en) * | 1995-02-10 | 1995-03-09 | Lai, John | Methods of and preparations for the treatment of ailments and disorders |
| EP1207840B1 (en) * | 1999-08-20 | 2004-10-13 | Howard Murad | Pharmaceutical compositions and methods for reducing the appearance of cellulite |
| EP2371372A1 (en) | 2010-04-01 | 2011-10-05 | Anrold Forbes | Methods of promoting appetite suppression using alkali metals |
| WO2016139530A2 (en) | 2015-03-04 | 2016-09-09 | Arnold Forbes | Compositions and methods for treating drug addiction |
-
1987
- 1987-08-14 FR FR8711579A patent/FR2619313B1/fr not_active Expired
- 1987-10-28 CH CH4221/87A patent/CH675684A5/fr not_active IP Right Cessation
-
1988
- 1988-08-04 AT AT88402036T patent/ATE72984T1/de not_active IP Right Cessation
- 1988-08-04 DE DE8888402036T patent/DE3868791D1/de not_active Expired - Fee Related
- 1988-08-04 ES ES198888402036T patent/ES2034321T3/es not_active Expired - Lifetime
- 1988-08-04 EP EP88402036A patent/EP0306377B1/fr not_active Expired - Lifetime
- 1988-08-08 AU AU20464/88A patent/AU625310B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2619313B1 (fr) | 1989-12-29 |
| AU2046488A (en) | 1989-02-16 |
| EP0306377A1 (fr) | 1989-03-08 |
| ES2034321T3 (es) | 1993-04-01 |
| DE3868791D1 (de) | 1992-04-09 |
| FR2619313A1 (fr) | 1989-02-17 |
| AU625310B2 (en) | 1992-07-09 |
| EP0306377B1 (fr) | 1992-03-04 |
| ATE72984T1 (de) | 1992-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bryan | Nitric oxide deficiency is a primary driver of hypertension | |
| Kovanecz et al. | Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats | |
| ES2311117T3 (es) | Combinacion de un inhibidor de dpp-iv y un compuesto ppar-alfa. | |
| Bryan | Functional nitric oxide nutrition to combat cardiovascular disease | |
| CA2285394A1 (en) | Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases | |
| BE1004168A3 (fr) | Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv. | |
| CA2859940C (en) | Method for administration of an anti tumor agent | |
| CN115803028A (zh) | 用于治疗慢性肾病的齐泊腾坦和达格列净的组合 | |
| US20250186476A1 (en) | Compositions Containing Adenosine Triphosphate (ATP) and Methods of Use | |
| CH675684A5 (forum.php) | ||
| FR3102058A1 (fr) | Utilisation de NMN pour la prévention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes | |
| JPH0761924A (ja) | 腸内細菌の血中転移を抑制する輸液製剤 | |
| CN113905726B (zh) | 能够激活蛋白质Klotho产生的包含柠檬酸盐和肉碱的组合物 | |
| FR2922109A1 (fr) | Composition pharmaceutique ou dietetique pour inhiber l'absorption intestinale du sucre. | |
| FR2485371A1 (fr) | Nouvelle composition a usage therapeutique a base de lysine et d'arginine | |
| CN109963559A (zh) | 舌下或颊部施用dim以治疗皮肤病 | |
| WO2012156599A1 (fr) | Utilisation du secnidazole dans le traitement des infections dentaires | |
| JPH08245403A (ja) | インシュリン抵抗性症候群治療用組成物 | |
| TW200538154A (en) | Combination of organic compounds | |
| EP1317922A1 (fr) | Preparation antipyretique renfermant du xylitol | |
| JP2005502690A (ja) | 癌治療についての４−ピリジルメチルフタラジンの使用 | |
| TWI841431B (zh) | 斯文豪蒂殼海綿萃取物用以製備供選擇性抑制口腔癌細胞生長的藥物的用途 | |
| JP2002275059A (ja) | 腎機能障害改善用アミノ酸組成物 | |
| FR3068601A1 (fr) | Utilisation de l'imeglimine pour la prevention et/ou ke traitement du carcinome hepatocellulaire | |
| Dakshin et al. | Multiple Dyselectrolytemia in a Chronic Alcohol Abuser: A Case Report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |